VYNE Therapeutics
VYNE
VYNE
33 hedge funds and large institutions have $14.3M invested in VYNE Therapeutics in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 12 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
11% less capital invested
Capital invested by funds: $16.1M → $14.3M (-$1.78M)
58% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 12
Holders
33
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$44.6K | |
| 2 | +$42.6K | |
| 3 | +$34.7K | |
| 4 |
PCM
Prelude Capital Management
New York
|
+$214 |
| 5 |
Barclays
London,
United Kingdom
|
+$190 |
Top Sellers
| 1 | -$740K | |
| 2 | -$270K | |
| 3 | -$90.3K | |
| 4 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$79.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$47.5K |